Inversago
AcquiredDeveloping next-generation CB1 blockade therapies for metabolic disease.
Montreal, Canada · Founded 2015 · $112.0M raised
- Headquarters
- Montreal
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Website
- inversago.com
- Total Funding
- $112.0M
- Last Round
- $70.0M Series COct 2022
- Rounds
- 3
- Acquisition Date
- Aug 2023
About
Inversago Pharma specialized in CB1 receptor blockade therapies for metabolic disorders. Acquired by Novo Nordisk in August 2023.
Summary
Inversago is a Biotech company based in Montreal, Canada, founded in 2015. It has raised $112.0M in total across 3 rounds, most recently a $70.0M Series C round in Oct 2022. Investors include Genesys Capital, Amorchem and New Enterprise Associates.
Tech & App Stack
5 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Aug 2023
Sign up to see all 4 rounds
Series A through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/inversago"><img src="https://indexed.vc/api/badge/company/inversago" alt="Inversago on Indexed.vc" width="260" height="76" /></a>